A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment ...
NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.
Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription ...
NEW YORK, Oct. 24 (UPI) --Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the development and progression of age-related macular ...
Returning from the 2024 American Academy of Ophthalmology Annual Meeting in Chicago, Dr Garg highlights several important studies on diabetic macular edema (DME). One key study focused on the ...
Ophthalmologist Frank Holz, the trial’s scientific coordinator, called the results a “milestone” in treating severe vision loss caused by age-related macular degeneration. “Prior to this ...
NT-501 implantation in patients with macular telangiectasia type 2 (MacTel2) is well-tolerated and correlates with a lower percentage of eyes with ellipsoid zone (EZ) loss at 72 to 108 months ...
It's been an incredible few months with a lot of pivotal data coming to light at Neurotech, our focus is on Macular Telangiectasia Type 2, which is, as many people know, a rare progressive bilateral ...